Wyllie's Treatment of Epilepsy: Principles and Practice-6판

In one convenient source, Wyllie's Treatment of Epilepsy: Principles and Practice provides a broad, detailed, and
cohesive overview of seizure disorders and contemporary treatment options. For this Fifth Edition, the editors have
replaced or significantly revised approximately 30 to 50 percent of the chapters, and have updated all of them. Dr.
Wyllie has invited three new editors: Gregory Cascino, MD, FAAN, at Mayo Clinic, adult epileptologist with special
expertise in neuroimaging; Barry Gidal, PharmD, at University of Wisconsin, a pharmacologist with phenomenal expertise
in antiepileptic medications; and Howard Goodkin, MD, PhD, a pediatric neurologist at the University of Virginia.

A fully searchable companion website will include the full text online and supplementary material such as seizure
videos, additional EEG tracings, and more color illustrations.

The book contains predominantly black-and-white illustrations, with some color illustrations

-도서목차-

Foreword
1 Atlas of pathologic substrates of epilepsy 3
2 Human nervous system development and malformations 13
3 Malformations of cortical development and epilepsy 37
4 Hippocampal anatomy and hippocampal sclerosis 55
5 Basic cellular neurophysiology 69
6 Mechanisms of epileptogenesis and experimental models of seizures 91
7 Genetic aspects of epilepsy and genetics of idiopathic generalized epilepsy 103
8 Epidemiologic aspects of epilepsy 109
9 The natural history of seizures 117
10 Neurophysiologic basis of the electroencephalogram 127
11 Localization and field determination in electroencephalography and magnetoencephalography 141
12 Application of electroencephalography in the diagnosis of epilepsy 169
13 Electroencephalographic atlas of epileptiform abnormalities 183
14 Classification of seizures 217
App Proposal for revised clinical and electrographic classification of epileptic seizures : Commission on
Classification and Terminology of the International League Against Epilepsy (1981) 222
15 Epileptic auras 229
16 Focal seizures with impaired consciousness 241
17 Focal motor seizures, epilepsia partialis continua, and supplementary sensorimotor seizures 257
18 Generalized tonic-clonic seizures 279
19 Absence seizures 305
20 Atypical absence, myoclonic, tonic, and atonic seizures 317
21 Epileptic spasms 333
22 Classification of the epilepsies 347
App Proposal for revised classification of epilepsies and epileptic syndromes : Commission on Classification and
Terminology of the International League Against Epilepsy (1989) 354
23 Symptomatic focal epilepsies 365
24 Idiopathic and benign partial epilepsies of childhood 373
25 Idiopathic generalized epilepsy syndromes of childhood and adolescence 391
26 The myoclonic epilepsies 407
27 Encephalopathic generalized epilepsy and Lennox-Gastaut syndrome 429
28 Rasmussen's encephalitis (chronic focal encephalitis) 441
29 Continuous spike wave of slow sleep and Landau-Kleffner syndrome 455
30 Epilepsy with reflex seizures 463
31 Less common epilepsy syndromes and epilepsy associated with chromosomal abnormalities 477
32 Neonatal seizures 487
33 Febrile seizures 511
34 Posttraumatic epilepsy 521
35 Epilepsy in the setting of cerebrovascular disease 527
36 Epilepsy in the setting of neurocutaneous syndromes 537
37 Epilepsy in the setting of inherited metabolic and mitochondrial disorders 547
38 Seizures associated with nonneurologic medical conditions 571
39 Epilepsy in patients with multiple handicaps 585
40 Epilepsy in the elderly 593
41 Status epilepticus 605
42 Psychogenic nonepileptic seizures 623
43 Other nonepileptic paroxysmal disorders 631
44 Antiepileptic drug development and experimental models 645
45 Pharmacokinetics and pharamacodynamics of antiepileptic drugs 655
App Selected drug interactions between antiepileptic drugs and other types of medications 665
46 Pharmacokinetics of antiepileptic drugs in infants and children 671
47 Initiation and discontinuation of antiepileptic drugs 681
48 Hormones, catamenial epilepsy, and reproductive and bone health in epilepsy
49 Treatment of epilepsy during pregnancy 705
50 Treatment of epilepsy in the setting of renal and liver disease 719
51 Monitoring for adverse effects of antiepileptic drugs 735
52 Pharmacogenetics of antiepileptic medications 747
53 Carbamazepine and oxcarbazepine 761
54 Valproate 775
55 Phenytoin and fosphenytoin 785
56 Phenobarbital and primidone 805
57 Ethosuximide 817
58 Benzodiazepines 829
59 Gabapentin and pregabalin 855
60 Lamotrigine 869
61 Topiramate 877
62 Zonisamide 891
63 Levetiracetam 901
64 Tiagabine 907
65 Felbamate 913
66 Vigabatrin 921
67 Adrenocorticotropin and steroids 931
68 Newer antiepileptic drugs 939
69 Less commonly used entiepileptic drugs 947
70 The ketogenic diet 961
71 Vagus nerve stimulation therapy 969
72 Issues of medical intractability for surgical candidacy 983
73 Recognition of potential surgical candidates and video-electroencephalographic evaluation 993
74 Magnetic resonance imaging techniques in the evaluation for epilepsy surgery
75 The intracarotid amobarbital procedure 1031
76 Metabolic and functional neuroimaging 1041
77 Intracranial electroencephalography and localization studies 1059
78 Hippocampal sclerosis and dual pathology 1069
79 Resection for uncontrolled epilepsy in the setting of focal lesions on MRI : tumor, vascular malformation, trauma,
and infarction 1087
80 Epilepsy surgery in focal malformations of cortical development 1103
81 Hemispherectomy : medications, technical approaches, and results 1111
82 Epilepsy surgery in the absence of a lesion on magnetic resonance imaging
83 Epilepsy surgery in infants and children 1143
84 Corpus callosotomy and multiple subpial transections 1159
85 Newer operative and stereotactic techniques and their application to hypothalamic hamartoma 1169
86 Outcome and complications of epilepsy surgery 1175
87 Cognitive effects of epilepsy and antiepileptic medications 1185
88 Psychiatric comorbidity of epilepsy 1197
89 Driving and social issues in epilepsy 1201
App Indications for antiepileptic drugs sanctioned by the United States Food and Drug Administration 1211